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Background and Objective. Mantle cell lymphoma is
a recently recognized histologic entity with specific
biological and clinical features. Clinically, the report-
ed unfavorable outcome of these patients has focused
attention on this category of non-Hodgkin’s lymphoma
(NHL). 
Design and Methods. The slide specimens of 69 NHL
patients, originally classified as Working Formulation
(WF) group B and E, were reviewed. The clinical fea-
tures at presentation, response to therapy, response
duration and survival were analyzed in cases reclas-
sified as MCL. The correlation between clinical and
histologic characteristics and the final outcome was
evaluated.
Results. Out of 69 cases, 34 specimens were reclas-
sified as MCL; in 6 patients, previously classified as
WF group B, the nodular pattern was confirmed; in 2
instances the blastoid form was recognized. After a
median follow-up of 35.7 months, the entire series
displayed a median overall survival of 41.2 months;
a significantly longer survival was associated with
the nodular histologic pattern, IPI score <2, response
achievement, and a higher Hb level. The vast major-
ity of patients received anthracycline-containing com-
bination chemotherapy. Complete remission rate was
38.8% and overall response rate was67.6%; response
achievement was significantly influenced only by Hb
level. Median response duration was 23.3 months. 
Interpretation and Conclusions. The present study
confirms the unfavorable clinical course of MCL and
the possible need for an alternative therapeutic strat-
egy for this NHL category. Therefore, the correct iden-
tification of MCL at diagnosis appears of relevance.
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Mantle cell lymphoma (MCL), a recentlyredefined category of non-Hodgkin’s lym-phoma (NHL) by the Revised European-Amer-
ican Lymphoma (REAL) classification concerns about
8% of NHL patients with specific clinical, morpho-
logic, immunologic, cytogenetic and molecular char-
acteristics.1,2 This entity has been previously record-
ed among centrocytic NHL in the Kiel classification3
and considered as low grade,4 while the Working For-
mulation (WF) did not recognize MCL as a distinct
entity.5 Moreover, pathologists in the United States
included this category among the lymphocytic lym-
phomas of intermediate grade of differentiation
group.6,7 The diffuse form represents the commonest
MCL histologic pattern.1,8 Furthermore, a follicular
form has been identified, together with its variant
mantle zone lymphoma, which constitutes the initial
phase of the disease.8-12 Finally, a very rare variant of
MCL, the so-called blastoid  form, characterized by
larger cells and a high mitotic index has been recog-
nized.12 Whether these different histologic patterns
correspond to distinct clinical outcomes is still ques-
tioned.11,13
Immunophenotypically, MCL B cells are CD5+
CD23–, a characteristic immunologic pattern distin-
guishable from follicular (CD5–) and from small lym-
phocytic lymphoma (CD23+).1 Finally, t(11;14)
(q13;q32), detectable in the majority of MCL cases,
represents the cytogenetic hallmark of the disease.1
This translocation involves the blc-1 oncogene14 with
the consequent overexpression of cyclin D1.15 Both
the unique histologic and biologic features also trans-
late into peculiar clinical characteristics, which dif-
ferentiate MCL from indolent NHL, because of the
former’s aggressive course, and from high grade NHL,
considering that no plateau is reached in the survival
curve with conventional chemotherapy.16,17
In this study, we reviewed histologic specimens
from WF B and E category patients referred to co-
operative institutions of the Gruppo Italiano per lo Stu-
dio dei Linfomi (GISL), with the aim of describing the
clinical features and prognostic factors of those cas-
es redefined as MCL.
Materials and Methods
Patients 
We decided to review slide specimens retrospective-
ly from patients previously classified as WF B and E
NHL, considering that the majority of MCL might be
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included in these subgroups. Out of 69 specimens 34
were reclassified as MCL by a panel of GISL patholo-
gists, according to the currently accepted REAL histo-
logic criteria.1 In 6 cases (17.6%), all previously classi-
fied as WF B NHL, a nodular pattern was confirmed;
28 (82.3%) displayed diffuse growth and 2 (5.9%)
exhibited the blastic variant with a diffuse pattern;
these last cases belonged to WF group E. Mantle zone
histologic architecture cases were not separately eval-
uated from those with a follicular pattern.
Staging 
At diagnosis all patients underwent chest x-ray, total
body computed tomographic scan, abdominal ultra-
sound and bone marrow biopsy to establish the stage
of the disease. The following clinical and laboratory
data were considered for the clinical and prognostic
evaluation: age, sex, site of biopsy, performance status
(PS) evaluated by the Karnofsky index, systemic symp-
toms, disease sites, stage and bulk, ESR, lactate dehy-
drogenase (LDH), hemoglobin (Hb), albumin, iron
and fibrinogen. By using the pretreatment risk factors
(age, PS, tumor stage, number of extranodal sites,
LDH) of the International Prognostic Index (IPI)18 patients
were stratified into two risk categories, ranking IPI score
0-2 as low risk  and score 3-5 as high risk groups.
Therapy
Treatment schedules varied over the years accord-
ing to GISL controlled clinical trials: aggressive sched-
ules with anthracyclines were used in 30 patients:
ProMECE-CytaBOM (26 cases), BACOP (1), CEOP
(1), chlorambucil plus epidoxorubicin (1), VEMB (1).
Less intensive therapy without anthracyclines con-
sisting of chlorambucil with or without interferon was
given to the remaining 4 patients.
Response to therapy
Complete response (CR) was defined by the dis-
appearance of any detectable sign of disease, partial
response (PR) as more than 50% reduction of the ini-
tial tumor mass, progression (PD) as the increase of
tumor mass while the patient was receiving treatment
and no response (NR) as failure to achieve CR or PR. 
Statistical analysis
The chi-square test (Fisher’s exact two-tailed test)
for 232 tables was used for overall comparison of
clinical responders versus non-responders. Survival,
calculated from the date of diagnosis, was assessed by
the Kaplan and Meier method. Difference in survival
between prognostic groups was evaluated in univari-
ate analysis by the log-rank test. For all analyses, the
variables age, albumin, iron, Hb, fibrinogen and ESR
were transformed into binary variables by using the
median as the cut-off value. All calculations were per-
formed using the SAS/STAT software package, release
6.06 of SAS Institute Inc., 1993.
Results
Table 1 shows the main clinical characteristics of
the patients at the onset of the disease. Twenty-four
patients were male and 10 female with a median age
of 56.3 years (range 29-80). B symptoms were pre-
sent in 35.2% and bulky disease in 14.7% of the cas-
es. Twenty-eight out of 34 (82.3%) patients were in
an advanced stage: 5 stage III and 23 stage IV. Sites
of extranodal involvement were 6 Waldeyer, 4 liver, 2
gastrointestinal tract, 1 lung, 1 brain, 1 kidney and 1
prostate. The spleen was enlarged in 41.1% and bone
marrow involved in 47.0% of patients. IPI, according
to our simplified stratification criteria, identified
60.6% of patients as having a low risk and 39.3% as
having a high risk score.
The majority of patients (30/34) received anthracy-
cline-containing regimens, while non-aggressive treat-
ment was administered to the remaining 4. Thirteen
patients (38.2%) achieved CR and 10 (29.4%) a PR
with an overall response rate of 67.6%. Six patients
did not respond (NR), 3 progressed (PD), 1 died
Table 1. Clinical features at diagnosis from 34 patients
affected by MCL.
Variable No./total %
Male sex 24/34 70.5
Age, > 60 years 17/34 50
< 80% PS 18/34 52.9
Abnormal LDH 17/33 51.5
Extranodal sites ‡ 1 4/34 11.7
Stage III and IV 28/34 82.3
High risk by IPI score 13/33 39.3
Bone marrow involvement 16/34 47
Spleen enlargement 14/34 41.1
B symptoms 12/34 35.2
Bulk (‡ 10 cm) 5/34 14.7
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Figure 1. Overall survival of MCL patients.
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Table 2. Univariate analysis of prognostic variables influ-
encing response achievement.
Variable CR+PR NR+PD Uni-
No. No. variate
p
Age, years (≤ 60 v > 60) 14 v 9 6 v 4 1.0
Sex (male v female) 18 v 5 5 v 5 0.2
Symptoms (A v B) 15 v 8 6 v 4 1.0
IPI score (0-2 v 3-4) 14 v 8 6 v 4 1.0
Bulk (yes v no) 3 v 20 2 v 8 0.6
WF group (B v E) 6 v 17 0 v 10 0.1
Therapy with anthracycline  (yes v no) 18 v 5 9 v 1 0.6
Albumin, g/dL (≤ 4.1 v > 4.1) 9 v 8 4 v 4 1.0
Iron, µg % (≤ 78 v > 78) 8 v 11 5 v 2 0.4
Hb, g/dL (≤ 12 v > 12) 8 v 13 8 v 2 0.054
Fibrinogen mg % (≤ 341 v > 341) 8 v 10 6 v 3 0.4
ESR (≤ 28 v > 28) 12 v 9 4 v 5 0.7
*Fisher’s exact test.
Table 3. Univariate analysis of prognostic variables for  over-
all survival.
Variable Probability Uni-
of overall survival variate
p
Age, years (≤ 60 v > 60) 0.50 v0.50 0.4
Sex (male v female) 0.45 v0.60 0.4
Symptoms (A v B) 0.59 v 0.23 0.3
IPI score (0-2 v 3-4) 0.65 v 0.23 0.0027
Bulky (yes v no) 0.40 v 0.52 0.7
WF group (B v E) 0.83 v 0.43 0.054
Therapy, anthracycline (w v w/o) 0.46 v 0.67 0.3
Response (CR+PR v NR+PD) 0.65 v 0.20 0.0125
Albumin, gr. % (≤ 4.1 v > 4.1) 0.29 v 0.58 0.5
Iron, µg % (≤ 78 v > 78) 0.36 v 0.62 0.2
Hb, gr % (≤ 12 v > 12) 0.31 v 0.62 0.0204
Fibrinogen mg % (≤ 341 v > 341) 0.36 v 0.50 1.0
ESR (≤ 28 v > 28) 0.56 v 0.40 0.1
*Log-Rank test.
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Figure 2. Overall survival of MCL patients stratified by his-
tologic subtype (WF B and E) and by IPI simplified score.
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Figure 3. Overall survival of MCL patients stratified by Hb
value and by response to chemotherapy.  
because of toxicity and 1 was lost to follow-up. Among
the variables evaluated in this study, only Hb level sig-
nificantly influenced the response achievement
(p=0.054 in univariate analysis) (Table 2). Ten
patients relapsed and the median length of remission
was 23.3 months, 23.4 months for CR and 23.0 for
PR. No factor was significantly associated with remis-
sion duration. After a median follow-up of 35.7
months 17 patients had died: 13 of disease-related
causes, 1 because of toxicity, 2 of infection and 1 of
unknown cause. The median overall survival was 41.2
months (Figure 1), with 35.9% of patients alive at 48
months. In univariate analysis (Table 3), a shorter sur-
vival was associated with WF group E histology and IPI
score >2 (Figure 2), absence of response and Hb ≤ 12
g/dL (Figure 3). Of note, when risk factors considered
by the IPI score were separately analyzed, only perfor-
mance status remained significant (p=0.035).    
Discussion
The histologic, biologic and clinical outcomes have
recently focused attention on MCL. In the present
study, 69 patients included in GISL controlled clinical
studies, originally defined as having B or E histology
according to the WF, underwent a review. Thirty-four
cases could be reclassified as MCL and their main clin-
ical characteristics and prognostic factors were ana-
lyzed. Although diagnostic criteria of MCL have now
been well defined,1 further evaluation and  confirma-
tion of its clinical characteristics and prognostic para-
meters could be useful, in order to improve the thera-
peutic strategy towards this NHL entity. The clinical
features of the present series are in line with those pre-
viously reported.12,13,16,19-24 Although all patients but
four were treated with anthracycline-based protocols,
the complete remission rate was 38%, relapses were
frequent and median overall survival was rather dis-
appointing (41.2 months). In this regard, the role of
anthracyclines in MCL treatment remains controver-
sial. Zucca et al.22 found that therapy with anthracy-
clines may give a benefit in terms of survival over chlo-
rambucil. On the other hand, no other retrospec-
tive12,13,16,19,21-25 or randomized20 study demonstrated
any survival advantage for MCL and centrocytic lym-
phoma patients treated with an aggressive protocol. 
Another matter of debate is the presence of a nodu-
lar pattern. In our series 17.6% of cases, originally
classified as WF group B, had a longer survival than
WF group E patients. Previously, it was reported that
a mantle zone pattern is associated with an early clin-
ical presentation, a favorable response to therapy and
a longer overall survival as compared to diffuse his-
tology.10,11,26 Contrariwise, other authors showed that
MCL patients with a nodular pattern, which is defined
by pathologists as an intermediate stage between
mantle and diffuse growth, had a clinical outcome
similar to patients with diffuse histology.13 This dis-
crepancy may be due to the fact that in the latter
study the mantle zone and follicular histologic pat-
terns were analyzed altogether.
In the present series, the median overall survival was
41 months, comparable to previous experiences in
which it ranged between 24 and 60 months.12,13,16,17,21-25,27
Several clinical parameters were reported as influenc-
ing overall survival in MCL.6,10,12,22-24,27-29 In our study,
univariate analysis showed that Hb ‡ 12 g/dL, IPI score
< 2 and response to therapy were significantly associ-
ated with a longer survival. Moreover, when a separate
univariate analysis of the five IPI components was per-
formed, PS was the only parameter with a significant
impact on overall survival. 
In conclusion, our study confirms that MCL affects
mainly elderly patients in advanced stage of disease
and with systemic symptoms. The poor prognosis of
these patients is probably due to the biology of MCL
cells, which overexpress cyclin D1 and lose, in the more
aggressive form, the wild type p53 gene product.30 So
far, common experience indicates that MCL is not
cured by conventional or purine analog therapy.21,29
Moreover, high dose chemo-radiotherapy with periph-
eral blood stem cell support fails to improve long-term
survival in these patients.31,32 Alternative approaches,
such as immunotherapy33 should be urgently evaluat-
ed in prospective trials or allogeneic stem cell trans-
plantation.34
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